Coronavirus Notebook: Global COVID-19 Summit To Press For More Funding For Vaccines & Treatments, WHO Calls For End To IP Waiver ‘Stalemate’
Executive Summary
CEPI has announced funding for a “variant-proof” vaccine being developed by a multidisciplinary consortium. The European Medicines Agency's new committee on drug shortages in health crises has held its first meeting, and the European Parliament’s new COVID-19 committee will quiz the health commissioner on the EU’s vaccines strategy and response to the pandemic.
You may also be interested in...
EMA Publishes List Of ‘Critical’ COVID-19 Products
A steering group set up by the EU regulator has produced a list of five vaccines and nine therapeutics that it deems essential for use in preventing and treating COVID-19. It will also draw up a list of critical medicines for use in emergency and intensive care during health crises.
COVID-19 Summit Sees Progress On Test-And-Treat, IP Licensing, & Funding Commitments
Announcements at the second Global COVID-19 Summit included a technology licensing agreement for vaccine and diagnostic products developed by the US NIH, a new partnership to boost the use of testing and antiviral treatments in less wealthy countries, and a flurry of new funding pledges from organizations and companies alike.
EMA To Draw Up 'Critical Medicine' Lists For Future Health Crises
As part of its expanded mandate, the EU regulator is identifying those medicines whose supply will need to be closely monitored during health crisis situations. The lists will draw on various information sources, including real-world evidence databases.